Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system
This landmark pharmacovigilance study reveals previously uncharacterized temporal and mechanistic patterns of antineoplastic cardiotoxicity, providing an essential evidence-based framework for cardiovascular monitoring strategies. The findings highlight critical intervention windows: immediate monitoring for fluoropyrimidines, intermediate surveillance for anthracyclines (2-6 months), and extended follow-up for agents like mitoxantrone (>12 months). These insights support the development of risk-stratified cardio-oncology protocols tailored to specific therapeutic classes.
Authors
- Jiahan Ke (ORCID: https://orcid.org/0009-0007-1573-3169)
- Yiran Rong (ORCID: https://orcid.org/0000-0002-8571-3872)
- Longyu Wang (ORCID: https://orcid.org/0000-0003-2733-7319)
- Jun Gu (ORCID: https://orcid.org/0000-0002-1847-7304)
- Huasu Zeng (ORCID: https://orcid.org/0009-0006-2714-9229)
- Min Wang (ORCID: https://orcid.org/0000-0002-6495-5637)
- Qing Li (ORCID: https://orcid.org/0000-0002-4982-1024)
- Xiaohan Qiu (ORCID: https://orcid.org/0009-0005-3737-7981)
Institutions
- Shanghai Ninth People's Hospital (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Therapeutic Advances in Drug Safety
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/20420986251401122
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39